# Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma

> **NCT02876978** · PHASE1 · UNKNOWN · sponsor: **CARsgen Therapeutics Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Lung Squamous Cell Carcinoma

## Interventions

- **GENETIC:** CAR-GPC3 T Cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02876978
- **Lead sponsor:** CARsgen Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2017-10
- **Final completion:** 2019-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2016-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02876978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02876978, "Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02876978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*